WO2008108756A1 - Sunscreen compositions - Google Patents
Sunscreen compositions Download PDFInfo
- Publication number
- WO2008108756A1 WO2008108756A1 PCT/US2007/005672 US2007005672W WO2008108756A1 WO 2008108756 A1 WO2008108756 A1 WO 2008108756A1 US 2007005672 W US2007005672 W US 2007005672W WO 2008108756 A1 WO2008108756 A1 WO 2008108756A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agents
- endocrine
- sunscreen
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 171
- 239000000516 sunscreening agent Substances 0.000 title claims abstract description 124
- 230000000475 sunscreen Effects 0.000 title claims abstract description 50
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 64
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 43
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 43
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 40
- 239000000598 endocrine disruptor Substances 0.000 claims abstract description 35
- 239000011787 zinc oxide Substances 0.000 claims abstract description 32
- 239000003974 emollient agent Substances 0.000 claims abstract description 31
- 210000003491 Skin Anatomy 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 26
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 22
- 239000000341 volatile oil Substances 0.000 claims abstract description 20
- 230000001120 cytoprotect Effects 0.000 claims abstract description 18
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 17
- 239000003921 oil Substances 0.000 claims abstract description 16
- 239000002199 base oil Substances 0.000 claims abstract description 14
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 14
- 150000002482 oligosaccharides Polymers 0.000 claims abstract description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 10
- 230000002766 immunoenhancement Effects 0.000 claims abstract description 9
- 230000002633 protecting Effects 0.000 claims abstract description 7
- 241000894007 species Species 0.000 claims abstract description 7
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims abstract description 5
- 229960005193 avobenzone Drugs 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 239000002981 blocking agent Substances 0.000 claims abstract 2
- 239000004811 fluoropolymer Substances 0.000 claims abstract 2
- 229920002313 fluoropolymer Polymers 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims description 55
- 239000006185 dispersion Substances 0.000 claims description 26
- 231100000507 endocrine disrupting Toxicity 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 22
- 229960005309 Estradiol Drugs 0.000 claims description 22
- 244000144927 Aloe barbadensis Species 0.000 claims description 20
- 241001116389 Aloe Species 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 150000003839 salts Chemical group 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 12
- -1 retinyl vitamin A palmitate Chemical compound 0.000 claims description 12
- 230000002124 endocrine Effects 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 10
- 235000013311 vegetables Nutrition 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 238000010998 test method Methods 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 230000004043 responsiveness Effects 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 230000002708 enhancing Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000010954 inorganic particle Substances 0.000 claims description 6
- 230000000699 topical Effects 0.000 claims description 6
- 229940029983 VITAMINS Drugs 0.000 claims description 5
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 5
- 239000000077 insect repellent Substances 0.000 claims description 5
- 230000002232 neuromuscular Effects 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamins Natural products 0.000 claims description 5
- 229940024606 Amino Acids Drugs 0.000 claims description 4
- 229960001031 Glucose Drugs 0.000 claims description 4
- 210000004927 Skin cells Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000003712 anti-aging Effects 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 230000006750 UV protection Effects 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000011164 primary particle Substances 0.000 claims description 3
- 230000004224 protection Effects 0.000 claims description 3
- 230000001681 protective Effects 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 230000037072 sun protection Effects 0.000 claims description 3
- 229960002747 Betacarotene Drugs 0.000 claims description 2
- 229940083828 Bioflavonoid drugs for capillary stabilizing Drugs 0.000 claims description 2
- 229940093797 Bioflavonoids Drugs 0.000 claims description 2
- 235000003880 Calendula Nutrition 0.000 claims description 2
- 240000001432 Calendula officinalis Species 0.000 claims description 2
- 239000010369 Cascara Substances 0.000 claims description 2
- 241001528248 Frangula Species 0.000 claims description 2
- 241000556215 Frangula purshiana Species 0.000 claims description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 229940010454 Licorice Drugs 0.000 claims description 2
- 229960005190 Phenylalanine Drugs 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229940045997 Vitamin A Drugs 0.000 claims description 2
- 229940011671 Vitamin B6 Drugs 0.000 claims description 2
- 229930003629 Vitamin B6 Natural products 0.000 claims description 2
- 229940046009 Vitamin E Drugs 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- 229940058505 cascara Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 235000014063 licorice root Nutrition 0.000 claims description 2
- 230000003000 nontoxic Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 125000002640 tocopherol group Chemical group 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 229930003799 tocopherols Natural products 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 150000003697 vitamin B6 derivatives Chemical class 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-α-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 235000013871 bee wax Nutrition 0.000 claims 3
- 239000012166 beeswax Substances 0.000 claims 3
- 235000020748 rosemary extract Nutrition 0.000 claims 3
- 229940092258 rosemary extract Drugs 0.000 claims 3
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims 3
- 229920001285 xanthan gum Polymers 0.000 claims 3
- 239000000230 xanthan gum Substances 0.000 claims 3
- 229940082509 xanthan gum Drugs 0.000 claims 3
- 235000010493 xanthan gum Nutrition 0.000 claims 3
- 108010015776 EC 1.1.3.4 Proteins 0.000 claims 2
- 229940088598 Enzyme Drugs 0.000 claims 2
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 claims 2
- 239000004366 Glucose oxidase Substances 0.000 claims 2
- 229940057428 LACTOPEROXIDASE Drugs 0.000 claims 2
- 102000028880 Lactoperoxidase Human genes 0.000 claims 2
- 108010023244 Lactoperoxidase Proteins 0.000 claims 2
- 235000019486 Sunflower oil Nutrition 0.000 claims 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 2
- 235000015155 buttermilk Nutrition 0.000 claims 2
- 235000019420 glucose oxidase Nutrition 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 235000010339 sodium tetraborate Nutrition 0.000 claims 2
- 239000002600 sunflower oil Substances 0.000 claims 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims 2
- 235000019871 vegetable fat Nutrition 0.000 claims 2
- 239000001993 wax Substances 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 229960002061 Ergocalciferol Drugs 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 229940107702 Grapefruit seed extract Drugs 0.000 claims 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 claims 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 235000017357 Uva orsina Nutrition 0.000 claims 1
- 240000000985 Vaccinium erythrocarpum Species 0.000 claims 1
- 235000011676 Vaccinium erythrocarpum Nutrition 0.000 claims 1
- 229940046008 Vitamin D Drugs 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229960001452 alpha-Tocopherol Acetate Drugs 0.000 claims 1
- CHIHQLCVLOXUJW-UHFFFAOYSA-N benzoic anhydride Chemical class C=1C=CC=CC=1C(=O)OC(=O)C1=CC=CC=C1 CHIHQLCVLOXUJW-UHFFFAOYSA-N 0.000 claims 1
- 235000020230 cinnamon extract Nutrition 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 239000005414 inactive ingredient Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 229960002366 magnesium silicate Drugs 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 230000000979 retarding Effects 0.000 claims 1
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims 1
- 235000019172 retinyl palmitate Nutrition 0.000 claims 1
- 239000011769 retinyl palmitate Substances 0.000 claims 1
- 235000019719 rose oil Nutrition 0.000 claims 1
- 239000010666 rose oil Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 235000010215 titanium dioxide Nutrition 0.000 claims 1
- 229910001929 titanium oxide Inorganic materials 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108020003112 toxins Proteins 0.000 claims 1
- 229950004578 vitamin A palmitate Drugs 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims 1
- 235000001892 vitamin D2 Nutrition 0.000 claims 1
- 239000011653 vitamin D2 Substances 0.000 claims 1
- 235000014692 zinc oxide Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 239000000654 additive Substances 0.000 abstract description 4
- 240000005513 Aloe vera Species 0.000 abstract 2
- 239000003995 emulsifying agent Substances 0.000 description 22
- 230000001076 estrogenic Effects 0.000 description 21
- 238000004166 bioassay Methods 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 17
- WSSJONWNBBTCMG-UHFFFAOYSA-N Homosalate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 14
- 229920002545 silicone oil Polymers 0.000 description 12
- 239000011435 rock Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 241000234295 Musa Species 0.000 description 9
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 9
- 125000000129 anionic group Chemical group 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 230000002588 toxic Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 229940071160 cocoate Drugs 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 5
- 108060001084 Luciferase family Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001603 reducing Effects 0.000 description 4
- 238000003530 single readout Methods 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical class OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940069521 Aloe Extract Drugs 0.000 description 2
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000000111 anti-oxidant Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 231100000693 bioaccumulation Toxicity 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 231100000049 endocrine disruptor Toxicity 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000005480 straight-chain fatty acid group Chemical class 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000004078 waterproofing Methods 0.000 description 2
- HEOCBCNFKCOKBX-CRAIPNDOSA-N (1S,4S)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1C=C1C(=O)[C@@]2(C)CC[C@H]1C2(C)C HEOCBCNFKCOKBX-CRAIPNDOSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- OXLXSOPFNVKUMU-UHFFFAOYSA-N 1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical compound CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC OXLXSOPFNVKUMU-UHFFFAOYSA-N 0.000 description 1
- VYZKQGGPNIFCLD-UHFFFAOYSA-N 3,3-dimethylhexane-2,2-diol Chemical compound CCCC(C)(C)C(C)(O)O VYZKQGGPNIFCLD-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- HEOCBCNFKCOKBX-SDNWHVSQSA-N 4-Methylbenzylidene camphor Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)C2(C)CCC\1C2(C)C HEOCBCNFKCOKBX-SDNWHVSQSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 Camphor Drugs 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 206010072082 Environmental exposure Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010049290 Feminisation acquired Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 240000005389 Glycyrrhiza glabra Species 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229960004881 Homosalate Drugs 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010021093 Hypospadias Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 229940078752 MAGNESIUM ASCORBYL PHOSPHATE Drugs 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- FBTSQILOGYXGMD-LURJTMIESA-N Nitrotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N Oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100003986 RBM17 Human genes 0.000 description 1
- 101710011807 RBM17 Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 240000003136 Rosmarinus officinalis Species 0.000 description 1
- 102100014887 SMNDC1 Human genes 0.000 description 1
- 101710011816 SMNDC1 Proteins 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003466 anti-cipated Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 230000001815 facial Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-L hexadecyl phosphate Chemical compound CCCCCCCCCCCCCCCCOP([O-])([O-])=O ZUVCYFMOHFTGDM-UHFFFAOYSA-L 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 238000004647 photon scanning tunneling microscopy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 229910052904 quartz Inorganic materials 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000001577 simple distillation Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002034 xenobiotic Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000000800 xenoestrogenic Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
Abstract
Sunscreen and sunblock formulations that provide cytoprotective and immuno-enhancing additives avoiding endocrine disrupting agents, (a) at least one inorganic sun-blocking or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient proven to be a non-endocrine disrupter; and (c) an oil component capable of protecting skin from harmful effects of radiation including sunlight and ultraviolet light wherein the oil is a carrier oil, an essential oil, or both are described. The formulations preferably include an essential oil of a naturally-occurring substance as well as suitable inorganic components including titanium dioxide, zinc oxide, silica or silicon dioxide, fluoropolymers, and mixtures thereof. Suitable organic components include butylmethoxy dibenzoylmethane. Cold-processed Aloe barbadensis Miller-Stockton, a single species of Aloe barbadensis containing glucose-rich mannose-containing oligosaccharide or oligosaccharides, can also be used. Test methodologies and results indicate specific differences from conventional formulations.
Description
Sunscreen Compositions
Field of Invention
This invention relates to sunscreens and sunblocking agents, generally, and, more specifically, to sunscreens and sunblocking agents which include cytoprotective additives and/or which do not include suspected or documented endocrine disruptive agents. The endocrine-disrupting nature of various active sunscreen or sunblock agents as well as non- active constituents that are used in the formulations, can be measured using a specific test known as a LUMI-CELL™ ER estrogenic cell bioassay system, which is also described herein.
Background
Although a tan has long been considered a symbol indicative of good health, excessive exposure of the human skin to sunlight is harmful. For this reason, many people use sunscreens and/or sunblocking agents to minimize their exposure to harmful rays.
A study by Margaret Schlumph at the Institute of Pharmacology and Toxicology at the University of Zurich first published in 2001, supports earlier health concerns regarding the use of endocrine disrupting organic substances in nearly all UV screening chemicals used in sunscreens. The association between the exposure and bioaccumulation of endocrine disruptor chemicals (EDCs) and their adverse effects on human and wild life populations has raised concern worldwide. Due to the detrimental effects of environmental exposure to EDCs, there is an obvious need to develop a relevant bioassay, which can both detect these chemicals, as well as provide a relevant estimate of their endocrine disrupting potency. Some examples of the effects of EDCs are: decreased reproductive success and feminization of males in several wildlife species; increased hypospadias along with reductions in sperm counts in men; increase in the incidence of human breast and prostate cancers; and endometriosis. Because these chemicals are ubiquitous, highly lipophilic, and often chlorinated, this ensures their persistent presence in the environment resulting in their bioaccumulation in the food chain.
It would be advantageous to provide sunscreen and sunblock formulations which do not include such endocrine disrupting agents. In addition, many of the non-active components or constituents also have been found to be endocrine disrupters and therefore it would be
advantageous to prepare formulations with both active and non-active ingredients that are free from endocrine disrupting compounds or agents. It would also be advantageous to provide cytoprotection to the skin using cytoprotective agents in the formulations. In addition, the use of immuno-enhancing compounds or agents is beneficial for sun protection formulations. The present invention provides such sunscreen and sunblock formulations.
Summary Compositions:
The composition of one embodiment contains at least the following components:
(a) an inorganic sun-blocking non-endocrine disruptive sunscreen agent such as micronized zinc oxide or titanium dioxide with particle sizes in the 20-300 nm range
(b) a non-endocrine disrupting cytoprotective emulsifier or emulsifier mixtures; (c) an oil component comprising a carrier oil, preferably an essential oil any of which are also non-endocrine disruptive and;
(d) at least one emollient, where the emollient may also be the cytoprotective emulsifier of (b) above
(e) sun boosting additives that are non-endocrine disruptors - especially silicone oils that are D5 based (Si-O- cyclics) and linear silicone oil based chemistry either alone or in combination with essential oils.
Sunblock and sunscreen compositions that are essentially free of endocrine disrupting agents, which provide cytoprotection to the skin, and are immuno-enhancing, are disclosed. In all embodiments, the compositions provide protection in the UV-A and UV-B long range and short range ultraviolet radiation spectrum. Ideally, the compositions provide coverage that is easily maintained, for example, by being waterproof and perspiration proof, and also easily applied and convenient to use, for example, invisible or nearly invisible once applied to the skin, non-staining and non-greasy. Further, the compositions ideally do not cause irritation. Advantageously, both active and inactive sun-block or sunscreen ingredients are void of any known or suspected endocrine disrupters.
Another embodiment is directed toward a colored sunscreen comprising: (a) at least one ultramarine pigment that imparts a color other than white to the emulsion with a titanium
dioxide or zinc oxide or possibly fumed or fused silica or even silicon dioxide (b) at least one sunscreen active agent in an amount effective to protect skin against the actinic radiation of the sun - this preferably being ZnO or Z-Cote (micronized particles - preferably nanoparticle sized to assure transparency); (c) no known or suspected endocrine disrupting organic substances; (d) a cytoprotective substance such as a glucose-rich mannose-containing oligosaccharide obtained from and used with aloe barbadensis Miller as an emulsifier; and (e) sufficient water to form other than a white colored emulsion; and sufficient dispersion to assure SPF of at least 15 and an SPF booster that itself is not an endocrine disrupter and shows no appreciable toxicity.
The amount of the ultramarine pigment in the composition can range form about 0.5 to 10 weight percent of the composition, preferably form 1 to 5 weight percent of the final formulation.
Optionally, the colored sunscreen emulsion can contain one or more additional ingredients, including emollients, waterproofing agents, dry-feel modifiers, insect repellants, antimicrobial preservatives and/or fragrances
In another embodiment, the compositions comprise known cytoprotective and immuno- enhancing oligosaccharides from aloe barbadensis Miller. The compositions can enhance the immuno-responsiveness of skin cells to UV light by using extracts of aloe or similar naturally-occurring substances, such as kukua nut extract and other similar naturally- occurring anti-inflammatory substances. In this embodiment, the substances are not processed, unless the beneficial immino-responsive effects are not lost during processing. Ideally, if processed, the substances are processed within a short time period (i.e., a few days) after harvesting, and the plants and subsequent extracts are kept cool (at or below room temperature) during processing. The immunoenhancing and cytoprotective agents are obtained from "cold-pressed" aloe which contains the beneficial oligosaccharides and provides an emollient base for the formulation. Other cytoprotective and immuno-enhancing agents, such as amino-acids, vitamins or pro-vitamins, nucleo- derivatives such as nucleosides or nucleotides and/or polymers thereof and vegetable extracts, can also be used. Amino acids that can be used include, for example, tryptophan, histidine, phenylalanine, and tyrosine. Vitamins and provitamins include vitamin B6, vitamin A, vitamin E, tocopherols, betacarotene, bioflavonoids, as well as the afroementioned nucleotides and polymers thereof.
Essential oils and plant extract include cascara, frangula, camomile, hyperic, calendula, elicriso, licorice or essential oils thereof, as well as the essential oils of frankincense and rosemary.
The compositions of this invention provide formulations having an SPF of at least 10 with a concentration level of titanium dioxide or zinc oxide or a combination of the two with or without silica or silcon dioxide and either with a treated or untreated hydrophilic surface of at least 4% and preferably reach SPF 15 or greater using 14% by weight of the inorganic sunblcoking substituents. The compositions of this invention exhibit extremely efficient uses of sunscreen components, particularly zinc oxide. Alternatively, higher levels of preferably micronized titanium dioxide or zinc oxide can be used if ultramarine pigments are added to the composition. These pigments are known to eliminate the whiteness and poor spreadability of known compositions. For the purposes of this invention, however, these pigments must be known to be non-endocrine disruptive as well as to not interfere with the cytoprotective influence of the oligosaccharide aloe extract. There are several ingredients that contribute to the unexpectedly high efficiency of the compositions blocking of UV radiation. It has been found, however, that only one known organic UVA protector, butyl- methoxydibenzoylmethane has been shown to be benign regarding activity in cells or developmental effects on animals.
The compositions may by necessity, include one or more of a select group of anionic emulsifiers. In particular, salts of certain fatty acids are useful in the formulations of this invention, preferably salts of saturated fatty acids and/or salts of straight-chain fatty acids. Alkali metal salts, alkali earth metal salts and amine salts are more preferable for use in the compositions. For example, stearic acid and its salts are useful as emulsifiers in the compositions.
More particularly, the following anionic emulsifiers could be useful in the compositions: sodium stearate, sodium lauryl sulfate, DEA cetyl phosphate, sodium dioctyl sulfosuccinate and the like. Most preferably, the emulsifier should be sodium stearate. While it is not completely understood why some salts of fatty acids result in an improved composition, it is theorized that salts of straight-chain fatty acids, (the fatty acids having a relatively high melting point, above 70° Celsius or higher), are preferable due to their structure. For example, salts of branched or unsaturated fatty acids are most likely not acceptable for use in
the compositions. These emulsifϊers have not been required in the current formulations but perhaps would be useful if the silicone oils or cocoate esters are not perceived as the best alternatives.
The anionic emulsifiers should be present in the compositions in an amount from about 0.01 to about 10%, more preferably 0.1 to about 7% and most preferably from about 0.5 to about 5%. There may be additional emulsifiers present, such as nonionic emulsifiers known to those of ordinary skill in the art such as sorbitan esters and ethoxylated sorbitan esters, ethoxylated fatty acids, fatty alcohols and ethoxylated fatty alcohol's, fatty glyceride esters and ethoxylated fatty glyceride esters and the like.
However, there may have to be at least one anionic emulsifier present in order to achieve the products associated with the compositions described herein. The fatty acid salt emulsifiers may be added to the composition as the salts, or the salt may be formed in situ.
In the case where salts of fatty acids are used, care should be taken to keep the pH of the compositions at a level above about 5, more preferably, above about 5.5. Maintaining the pH at this level will ensure that these anionic emulsifiers remain in the salt form, which is important in retaining the stability and efficacy of the composition.
Preferably, the carrier oil which is more preferably an essential oil, should be present in the composition in an amount of between about 0.1% and about 10%. More preferably, it should be present in the amount of between about 1% and about 5%. Most preferably, it should be present in the amount of between about 2% and about 3%.
For conventional UV-protection formulations, if there is an oil phase should contain at least two materials, the carrier oil or essential oil and a conventional emollient known to those of ordinary skill in the art as useful in sunscreen products, such as mineral oils, ester oils, vegetable oils, silicones, synthetic emollients such as fatty acid esters and the like. For the present invention, the use of a cold pressed aloe barbadensis Miller and specifically the Stockton species is to be substituted as an emollient or can be used in combination with the oils or synthetic emollients that are proven to be non-endocrine disrupting as well as not interfering with augmenting the cytoprotective enhancing effects of the known effective oligosaccharide aloe extract. The emollient should be present in the formulation in a ratio to
the carrier concentration of from about 1 : 1 to about 3 : 1 , most preferably, about 2:1. The carrier oil and the emollient should compose from about 2% to about 20% of the total composition weight.
The use of aloe as both an emollient and a surfactant/dispersion agent together with either micronized ZnO, titanium dioxide, silicon dioxide, PTFE or other fiuoropolymers, silica, etc. (inorganic or acceptable organic sunblocking agents) in the manner outlined above is unique and novel. The addition of silicone oils that are neither toxic or endocrine disrupters or other SPF boosting agents that meet the same requirements is also unique to this invention and has heretofore not been seriously considered or explored.
The compositions of the embodiments described can be incorporated into various cosmetic and personal care products such as hand and body lotions, oils, ointments, lip balm products, facial cosmetics and the like. The base formulations may also be used as carrier compositions for active topical agents having dermatological effects, including depigmentation agents, anti- aging ingredients, antifungal agents, antimicrobial agents, insect repellents and the like. For example, depigmentation agents can include magnesium ascorbyl phosphate or hydroquinone but only used in the final composition if these agents are shown not to be endocrine disrupters per the testing criteria established herewithin. Anti-aging agents can include retinoid compounds and alpha-hydroxy acids again only if these agents are shown not to be endocrine disrupters. Anti-fungal agents that can be included in the compositions of this invention include azole compounds including ketoconazole and the like again only if these agents are shown not to be endocrine disrupters. Anti-microbial agents include triclosan, an unknown agent regarding cytotoxicity or endocrine disruption function. Insect repellant fragrances can be included in the compositions of this invention again only if these agents are shown not to be endocrine disrupters.
An element which should be present in all compositions and embodiments is an inorganic sunscreen compound, such as titanium dioxide, zinc oxide or combinations thereof. Possible other inorganics include the use of fused or fumed silica or even silicon dioxide. Preferably, titanium dioxide and zinc oxide and silica or silicon dioxide should be used having a primary particle size from of less than about 300 nm in diameter. It should be present in the composition in the amount of from about 2% to about 25%. More preferably, it should be present in the amount of from about 2% to about 15%. Most preferably, it should be present
in the amount of from about 3% to about 10%. The inorganic sunscreen compound should be oil dispersible, and may be present with or without surface coating.
The ratio of titanium dioxide or zinc oxide to the weight of the carrier oil and the emollient combined should be from about 0.3 : 1 to about 1:1. Most preferably, the ratio should be between about 0.5:1 and 2:3.
Method of Making
It has been determined that a dispersion of ZnO or combinations of ZnO, TiO2, and/or silica or silica dioxide can be accomplished using aloe barbadensis Miller by first blending the inorganic particles (micronized or otherwise) at a high speed with for example, a Waring blender, followed by the addition of vegetable glycerin or suitable other products including cocoate esters (derivatives of coconut oil) or other oils to ensure complete dispersion and high speed mixing with for example an IKA mixer at speeds up to an including 2000 rpm. A dispersion without the cocoate ester has shown no known endocrine disrupter concentrations as determined by the LumiCell methodology.
To provide the much needed SPF/IRF/NED dispersion using the method outlined herein is critical to the invention and critical to the needs of an industry which is striving to make an "all natural" sunscreen or sunblock formulation. The industry currently formulates using "pre-fabricated" dispersions in that the dispersions are normally purchased from a secondary source and mixed in with existing lotions, pastes, cremes, etc. This technique is unacceptable and teaches away from the present invention, in that the dispersions themselves contain endocrine disrupters and generally toxic (cell killing) chemicals. Manufacturers using such a technique should not claim an "all natural" composition, and certainly not an endocrine- disrupter free composition.
It has also been determined that it is quite difficult, if not impossible, using current dispersion systems for micronized TiO2, ZnO, SiO2 and the like, that are endocrine-disruptive free. As discussed below, the endocrine disrupters in the Lumi-cell test technique have been found to kill cells. Therefore, in essence, using one of several definitions of toxicity - the killing of cells or adverse effects occurring as a result of repeated daily dosing of a chemical or
exposure to the chemical, for part of an organism's lifespan - the dispersions themselves are toxic.
A particular embodiment includes the use of aloe, not only as an emollient, but also as a very effective dispersing agent for the inorganic micronized (and larger) sunblock active agents. High speed shearing (accomplished in a Waring blender for example), followed by high speed mixing (up to 2000 rpm with an IKA mechanical stirrer for example) provides a consistent, usable, and easily blendable inorganic/organic dispersion free of any known toxic substances (if the aloe source and inorganic particle source is well documented and controlled). The dispersion is essential in providing sufficient homogeneity and SPF values with any associated non-active cream, lotion, gel, spray, etc. that is used to provide a formulation consistent with the basis of the present invention.
To provide the proper SPF value, it is also necessary to enhance or boost the SPF number using boosting agents. These may also be endocrine disrupters or toxic (cell-killing) or both and it has been discovered that at least one silicone oil - Dow Corning 1401 - (40-70% Decamethylcyclopentasiloxane and 30-60% octamethylcyclotetrasiloxane) is also essentially non-toxic (in terms of killing cells) and non-endocrine disrupting as shown below. The SPF boosting capabilities of silicone oils has been documented and known, but the ability to determine the associated toxicity or estrogenic potential or endocrine disrupting ability has never before been understood or tested. It is likely that other silicone oils and perhaps derivatives of other natural occurring substances that can provide dispersion capabilities to enhance SPF - such as cocoate esters (derived from coconut oil) or other essential oils may be determined to be free of endocrine disrupting capabilities.
As stated above, recent studies have confirmed the suspicion that endocrine disrupting agents exist in currently available sunscreen formulations including; benzophenone-s, homosalate, 4-methyl-benzylidene camphor, octyl methoxycinnamate, and octyl-dimethyl-PABA. AU of these substances, in fact, made cancer cells grow more rapidly and three caused developmental effects in animals. Therefore a non-endocrine disrupting UV protective formulation should include the use of inorganic sun-block agents, such as titanium dioxide and/or zinc oxide. A recent development in the reduction of particle sizes of ZnO has resulted in microfine essentially clear ZnO when applied to the skin. Formulation in the family
known as Z-Cote which is a trademarked composition sold by BASF is one such example of a micronized zinc oxide available today.
Therefore the ultimate UV-protective formulation would safely block or screen UV light, enhance the immune responsiveness of the skin in the absence or presence of UV, and ensure the user that there is no endocrine disrupting substance present so that immuno-reponsiveness is not impaired in the presence of UV light.
One method of making the sunblocking agent inorganic/organic dispersion is as follows:
1. hi a blender (waring or large manufacturing grade) add at least 14% by weight of micronized ZnO (with or without surface modification and with or without titanium dioxide or silica or silicon dioxide) into at least 24 ounces of pure cold pressed aloe barbadensis Miller (and preferably the single species - Aloe Barbedensis Miller- Stockton) and blend for at least one hour. It is preferred to keep the blending at or below room temperature so the aloe efficacy does not degrade.
2. Either while blending, or subsequent to that, optionally a silicone oil or essential oil or both can be added for SPF boosting. Because of "D4" issues , a D5 component silicone oil such as Dow Corning 1501 or even the linear Dow Corning 2-1184 silicone oil that has the same volatility as the D4 compounds may be even less toxic and perform well as SPF boosting agent. For the later 2 components there are no known toxic issues and the data for these are readily available from Dow Corning.
3. After blending, the dispersion should be transferred to a high speed mixing facility capable of 2000 rpm and mixed for another minimum of 1 hour. At this point the dispersion can be mixed with a preformulated and mixed lotion, creme, paste, etc. that will now incorporate the addition of the high SPF dispersion.
4. Blending should also be accomplished at or below room temperature in a chilled vessel if possible. Again, it is desirable to keep the polysachharides and other biologically active and healthful components of the aloe from degrading in the presence of the heat of mixing.
The final formulation can then be transferred to any suitable container and preferably refrigerated until distributed for use.
The formulations of this invention may be prepared using one of at least two methods: a two- vessel method, in which the oil and aloe or water phases are individually prepared, and a one- vessel method into which all ingredients are added in selected specific order. Any of these processes that will produce a smooth uniform, white to light ivory emulsion are satisfactory as long as the inorganic particles are sufficiently dispersed to provide adequate SPF values. When combined with ultramarine pigments, the color will change and also provide a clear appearance (using the micronized inorganics) as the composition is applied to the skin.
In accordance with the two- vessel process, an aloe or water phase is prepared by measuring deionized water into a beaker and mixing. The elements of the water phase, including emulsifiers and humectants, chelators, thickeners, waterproofing agents, neutralizing agents and antioxidants should be added and the solution heated. If an anionic emulsifier is used it may be placed into the water phase or into the oil phase, depending upon the nature of the emulsifier. The oil phase is prepared separately in another vessel, including the anionic emulsifier, carrier oil, emollient and inorganic sunscreen agent. The two phases should then be held at a relatively low temperature and mixed.
In the one-vessel process, the aloe-water and oil phases may be made in the same vessel, provided that the components are added in an appropriate order. For example, the aloe-water phase should be created first, adding water and aloe and ZnO or other sub blocking inorganic additives and optionally certain emulsifiers which are compatible with the aloe -water phase to the vessel. The oil phase components may be added, including, optionally, anionic emulsifiers if they are oil phase compatible and the carrier oil, as well as any additional oil- phase emulsifiers, antioxidants and/or emollients that may be desired and if necessary, with additional ZnO or TiO2, etc. The temperature should be kept at or below room temperature and should be maintained at this level for about 15 minutes - but longer period of stirring, mixing and blending are desirable. After cooling the pH may then be checked and adjusted if needed. Essential oils may also be added later in very small amounts to provide fragrance of most any naturally occurring plant, crop, fruit, or nut. The essential oils are often obtained by simple distillation.
It should be emphasized that SPF values of 15 or greater can be achieved solely by blending and subsequent mixing of aloe with vegetable glycerine (or glycerol as it is also known) and that we have achieved a superior product using this technique. This would be the so called "aloe-water" phase that would be subsequently mixed at high speed with the so-called "oil- phase". Blending would be accomplished using only the aloe-water phase and in so doing, the aloe would not be necessarily diluted with water until after the full addition and blending of the inroganic sunblocking agents. Water dilution during or after blending is acceptable but not necessary and in some cases it may be undesirable.
Testing and Rating Systems;
One current measure of effectiveness of a sun protective product is indicated by its sun protection factor (SPF). The sun protection factor is the ratio of the amount of exposure (dose) required to produce a minimal erythema reaction in protected skin to the amount required to produce the same reaction in unprotected skin. The absolute dose differs for each individual. Some essential oils may also provide SPF boosting capabilities as included above.
The compositions and resulting formulations described herein not only protect the wearer from the harmful effects of the sun, but actually strengthen the wearer's 'neuro-muscular response'. One test method, 'Applied Kinesiology', has been used to test a user's neuro- muscular response to sunblock formulations. Applied kinesiology (AK) is a form of diagnosis using muscle testing as a primary feedback mechanism to examine how a person's body is functioning.
A more complete rating mechanism than the SPF rating method is suggested here. The immuno-response rating system could be a simple 0-10 value, with 10 applying to a substance within the UV-protective composition that is most beneficial to boosting skin cell immune responsiveness to carcinoma, melanoma, etc. (for instance).
A UV-protective formulation or composition that may inhibit normal endocrine function(s) is at least undesirable, and at most a potential health threat to millions who continue to apply such a formulation or composition directly to their skin. Although the SPF value may be high, the potential for endocrine disruption from existing formulations utilizing higher
concentrations of active sunscreen agents may also be high and again this poses the possibility of another ranking system.
The continued and growing concern regarding estrogenic potency of sunscreens and their components associated (non-active) components has led to recent studies reviewing the "active" components of sunscreens such as 3-(4-methylbenxylidene) camphor (4-MBC), Octyl-Methoxycinniamate, and Benzophenone-3 have shown them to be highly estrogenic in assays such as uterine wet weight, cell height, and cell proliferation assays. Studies by Janjua et al. (2004) have shown these compounds in urine and blood plasma after topical application. Janjua et. al. (2004) also found changes in hormone (estradiol and testosterone) levels of participants after topical application. In a recent study conducted while further developing this patent application, several sunscreens currently marketed as well as the "non- active" sunscreen components were tested for estrogenic potency (or endocrine disruptive potential). The popular sunscreens tested include: Coppertone SPF 8; Coppertone SPF 15; Coppertone SPF 30 (Endless Summer); Banana Boat SPF 15; Banana Boat Kids SPF30; Hawaiian Tropic SPF 8; Coppertone Water Babies SPF 45; Banana Boat Baby Magic SPF 50; Hawaiian Tropic Baby Faces SPF 50+; and 3rd Rock Sunblock ™ SPF 30. The 3rd Rock formulation conforms to the requirements described in the present invention. The "non- active" components are compounds used in sunscreens and sunblocks that do not directly protect from UV damage and these include: Lexorez 200 (for dispersion and water resistance); ABIL Wax 9801 (emollient and improves SPF response); TEGO care PS (emulsifϊer); ABIL WE-09 (Emulsifier - that may boost SPF); KOBO CM3K40T4 (boosts SPF); Lanol 84D Dioctyl malate (allows for smooth texture - stabilizer); Dow Corning 344 (Lubricant and dispersant); Dow Corning 1401 (Lubricant. Both are silicone oils.
In ranking potential endocrine disruption substances, again the 0-10 rating is useful with 0 being the desired criteria that a consumer would want to purchase to ensure consumption of a quality product that is also completely safe in terms of potential adverse health effects regarding the endocrine disrupters.
Based on the results shown in Figures 1 and 2 and described below, regarding the LumiCell technique and testing, a logarithmic-type scale is proposed as follows;
01= a β-estradiol equivalent of less than 10 ng/g
2-3 = a β-estradiol equivalent of greater than 10 ng/g but less than 30 ng/g 4-5 = a β-estradiol equivalent of greater than 30 ng/g but less than 50 ng/g 6-7 = a β-estradiol equivalent of greater than 50 ng/g but less than 70 ng/g 8-9 = a β-estradiol equivalent of greater than 70 ng/g but less than 90 ng/g 10 = a β-estradiol equivalent of greater than 100 ng/g
Therefore, also as part of the present invention, a rating system for UV-protective compositions is proposed that includes;
SPF value - 15 or greater desired
Immuno-responsiveness factor (IRF) - 5 or higher desired (greater than 0)
Non-endocrine disrupter factor (NED) - 0-1 desired
AU earth grown ingredients in the composition and resulting formulation
The immuno-repsonsi veness factor (5 or higher) depends on the concentration of immuno- enhancing ingredients or components in the composition and resulting formulation. It is possible to quantify these constituents either during or after formulation is completed. The simplest technique is to quantify these components before formulation is initiated, when the composition has been finally decided upon.
This rating system has particular relevance to the newly discovered methods reported here required to process a dispersion capable of ensuring an SPF 15 or greater value without sacrificing the need to retain an "all earth grown" or "all natural" composition.
The foregoing examples serve as illustrations of the compositions of this invention, however, they do not limit the scope of the invention described herein.
Brief Description of the Figures
Figure 1 is a plot illustrating the estrogenic potential concentration of popular sunscreens and a sunblock using an β-estradiol equivalent of nanograms per gram (of sunscreen) (ng/g) scale.
Figure 2 is also a plot illustrating the estrogenic potential concentration for "non-active" sunscreen components using a β-estradiol equivalent of nanograms per gram (of the inactive) (ng/g) scale.
Detailed Description of the Figures
Shown in figure 1 is a plot of the estrogenic potential of popular sunscreens measured using β-estradiol equivalents (ng/g). The popular sunscreens that were tested are Coppertone SPF- 15™ [101], Hawaiian Tropic SPF-8™ [102], Hawaiian Tropic Baby Faces 50+™ [103], Coppertone SPF-30 (Endless Summer) ™ [104], Coppertone SPF-8™ [105], Banana Boat 15™ [106], Banana Boat Baby Magic 50™ [107], Banana Boat Kids 30™ [108], Coppertone Water Babies 45™ [109] and 3rd Rock Sunblock™ [110]. In all cases, except 3rd Rock Sunblock™ [110], there was a measurable and significant β-estradiol equivalent.
Shown in figure 2 is a plot of the estrogenic potential of "non-active" sunscreen chemical components also measured in β-estradiol equivalents (ng/g). The "non-active" components that were measured are Dow Corning 344™ [201] a cosmetic dispersant that is primarily cyclopolydimethylsiloxane. Other components are ABIL Wax 9801™ [202], an emollient; dispersing agent Lexorez 200™ [203], which is a trimethylpentanediol/adipic acid/glycerin crosspolymer; ABIL WE-09™ [204], an emollient; Tego Care PS™ [205] a methyl glucose sesquistearate emollient; Lanol 84D™ [206] which is a stabilizer comprised primarily of dioctyl malate; KOBO CM3K40T4™ [207] which is a composition of cyclopentasiloxane, titanium dioxide, PEG 10 dimethicone, alumina and methicone used primarily as an SPF booster; and Dow Corning 1401™ [208], a dispersant fluid of cyclomethicone and dimethiconol that also has SPF boosting properties.
EXAMPLES
Suitable Testing for Endocrine Disruption
In May of 2002, Xenobiotics Laboratories (XDS) of Durham, North Carolina submitted preliminary data to ICCVAM for review as a validated regulatory method using their LUMI- CELL™ ER bioassay in response to the Federal Register Notice (Vol. 66, No. 57/Friday, March 23, 2001) as a HTPS method for estrogen active compounds10. In March of 2004 SACATM gave the LUMI-CELL™ ER bioassay a high priority for validation. In April 2004 the final report on the assay was given to ICCVAM. In March 2005, ICCVAM entered the LUMI-CELL™ ER bioassay into a double blind international validation study using one lab
in the European Union, Japan, and the United States. Next, studies were undertaken in which XDS' s LUMI-CELL™ ER estrogenic cell bioassay system was used for high throughput screening (HTPS) analysis sunscreens. The results demonstrate the utility of XDS' s BGlLuc4E2 LUMI-CELL™ ER bioassay HTPS system for screening cosmetics for estrogenic/antiestrogenic activity.
There has been a growing need for a fast, reliable, inexpensive method to detect EDCs (endocrine disrupters) in the environment. As part of the present invention, we report a fast, reliable, relatively inexpensive high throughput cell based recombinant bioassay screening method (LUMI-Cell™ ER bioassay) to determine the level of xenoestrogenic EDCs for any cosmetic creme, lotion, paste, etc.
Sunscreen components were purchased from the Inolex Chemical Co., Goldschmidt Chemical Corp., Kobo Products Inc., and Dow Corning. Sunscreens were purchased at WaI- Mart.
LUMI-CELL ™ER Bioassay. The BGlLuc4E2 cell line was constructed as previously described by Rodgers and Denison (2000). Briefly, BGl cells were stably transfected with an estrogen-responsive luciferase reporter gene plasmid (pGudLuc7ere) and selected for using G418 resistance9.
Cell Culture and Bioassay Plates. BGlLuc4E2 cells were grown in RPMI 1640. The cells were transferred into flasks containing DMEM media (supplemented with 5% carbon stripped fetal calf serum and G418 sulfate solution), and incubated for four days before harvesting for BGl Luc4E2 bioassay plates. The cells were then plated in 96 well plates and incubated at 37° C for 24-48 hours prior to dosing.
Endocrine Extraction Procedure: One gram of each of the lotion components and 0.5 g of each of the sunscreens was placed in MeOH rinsed scintillation vials. Two and 4-gram aliquots of the 3 rd Rock Sunblock were also tested. Twenty ml of MeOH was added to each scintillation vial and sonicated for 20 min. Fractions of these extractions, ranging from 1:10 to 1:80,000 were tested. Recoveries were determined using IOng 17β-estradiol spiked into
3rd Rock Sunblock prior to extraction with 20 ml MeOH compared to IOng 17β-estradiol spiked into 20 ml MeOH.
Bioassay Dosing Process. Once the assay plate completed its incubation, the media solution in each well was removed and two hundred microliters of DMEM containing the indicated concentration of the desired chemical to be tested was added to each well. The plate was then incubated for 20 hours before analysis of luciferase activity.
Bioassay Analysis by Berthold Luminometer. After lysing the cells (Promega lysis buffer), the luciferase activity was measured in a Berthold Orion Microplate Luminometer, with automatic injection of 50 microliters of luciferase enzyme reagent (Promega) to each well. The relative light units (RLUs) measured were compared to that induced by the 17beta- estradiol standard after subtraction of the background activity. Each compound was tested at least three times on three different sets of plates and the EC50 value in mmol/ml was determined using the Microsoft Excel Forecast function.
To ensure that our claims have scientific basis and merit, 13 sunscreen products and 8 "non- active" lotion components were tested for estrogenic potency. The samples were tested at 4g, 2g, Ig, 0.5g, and O.lg. The 0.5g aliquot was selected for sunscreens and Ig for "non-active" components due to it showing the most activity with the least toxicity. The 3 rd Rock
Sunblock SPF 30™ (11) was used as a negative control due to it previously testing as a non- detect. The 3rd Rock Sunblock SPF 30 was also used in recovery determinations. This was performed by dividing the average RLU for the IOng 17β-estradiol spiked 3rd Rock Sunblock SPF 30 by the IOng 17β-estradiol spiked into 20 ml MeOH. The average recovery was found to be 77.4%.
All of the sunscreens detected positive for estrogenic activity with the exception of 3rd Rock Sunblock, which was shown as a non-detect at less than 0.308 pg/g 17β-estradiol equivalent. The sunscreen with the highest estrogenic potential was Coppertone Water Babies SPF45 at 948.66 ± 176.62 ng/g 17β-estradiol equivalent Based on our test results, the order of estrogenic potency appears to be: Coppertone Water Babies 45 > Banana Boat Kids 30 > Banana Boat Baby Magic 50 > Banana Boat 15 > Coppertone SPF 8 > Coppertone SPF 30 (Endless Summer) > Hawaiian Tropic Baby Faces 50+ > Hawaiian Tropic SPF 8 >
Coppertone SPF 15 > 3rd Rock Sunblock SPF 30. These results are graphically depicted in Figure 1
Only 3 of the "non-active" components showed any activity with only Lexorez 200 showing any significant estrogenic potency. The others showed very high detection limits due to their toxicity. These results are summarized and depicted in Figure 2
It has therefore been demonstrated that the "non-active" components contribute to a portion of the estrogenic potency of many sunscreen formulations. However, a significant portion of the estrogenic potency remains attributed to the "active" components of the same formulations. Further investigations that include testing "active" and "non-active" components for more detailed analysis regarding estrogenic potency ratios are anticipated. It is apparent from the foregoing results that the test methodology enables one to determine the estrogenic potency of any skin product, not just that of one designed for sun protection. It is known that lotions, shampoos, cleansing agents, cremes, sprays, etc. for human and animal skin contact for various uses, contain numerous endocrine disrupting components. Therefore, these embodiments include a test methodology to determine levels of toxicity (as defined by killing cells) that determines estrogenic potency and therefore also the propensity for and concentration of endocrine disruption for any lotion, creme, paste, spray, etc. for cosmetic use with or without suncare protection.
The use of silicone oils or other SPF boosting agents, such as the cocoate esters, are believed to be useful in providing SPF values of 30 or higher. The well known and commercially available "SPF boosters" have almost without exception proven to be toxic or endocrine disrupters or both and the present embodiments include a scientifically accepted and peer reviewed method to assure the use of only SPF boosters that are neither toxic nor endocrine disrupters.
Suitable Testing for SPF Values
Testing for SPF is well known and involves either in-vivo or in-vitro methods. The in-vitro methodology is less commonly accepted and includes the use of instrumentation that delivers certain focused wavelengths of UV light to artificial skin or other substrates and measures absorbance or reflectance. In-vivo measurements are still most common and includes
normally a patch test where humans are exposed to UV light that mimics sunlight. The time it takes for the subject to receive a slight reddening of the skin is then multiplied by 10 to determine the SPF value.
Suitable Testing for Cytoprotectiveness
Testing for cytoprotectiveness can be accomplished by numerous methods including cytokine testing. One such example involved correlation with a reduction in the level of measurable nitrotyrosine. A powerful oxidant peroxynitrite (PN) from the reaction of superoxide anion with nitric oxide found catalysts to be cytoprotective against endogenously generated PN in endotoxin-stimulated RAW 264.7 cells as well as in dissociated cultures of hippocampal neurons and glia that had been exposed to cytokines. Studies thus provide compelling evidence for the involvement of peroxynitrite in cytokine-mediated cellular injury and suggest the therapeutic potential of PN decomposition catalysts in reducing cellular damage at sites of inflammation. Testing for cytoprotectiveness of suncare products such as the compositions and formulations included in this disclosure could be similarly performed to determine if skin cell damage is reduced or eliminated.
Claims
1. A formulation comprising combining; (a) at least one inorganic sun-blocking or sunscreen agent that is not endocrine disrupting, (b) at least one emollient that is not endocrine disrupting ; and (c) an oil component capable of protecting skin from harmful effects of radiation including sunlight and ultraviolet light wherein said oil is a carrier oil, an essential oil, or both.
2. The formulation of claim 1, wherein said emollient consists essentially of aloe, water, and vegetable derived glycerine.
3. The formulation of claim 1, wherein the emollient comprises aloe barbadensis Miller or a single species of aloe barbadensis Miller, or aloe barbadensis Miller-Stockton present in a concentration of at least 5% by either weight or volume to inhibit loss of skin immunocompetency when applied to the skin.
4. The formulation of claim 1, further comprising one or more additional components selected from sunless tanning agents, anti-microbial agents, de-pigmentation agents, anti- aging agents, anti-fungal agents, insect repellents and combinations thereof.
5. The formulation of claim 1, wherein the inorganic sun-block agents are selected from the group consisting of titanium dioxide, zinc oxide, silica, silicon dioxide, fluoropolymers, and mixtures thereof, and said inorganic agents are micronized.
6. The formulation of claim 5, wherein the inorganic sun-block agents have a primary particle size of less than about 30 nm.
7. The formulation of claim 6, wherein the emollient is a salt of a not endocrine disrupting fatty acid.
8. The formulation of claim 1, wherein the formulation has a pH has a range of about
5 to about 8.5.
9. The formulation of claim 1 having a Sun Protection Factor (SPF) of at least 10, an immuno- responsiveness factor (IRF) of greater than zero, and a non-endocrine disrupter (NED) factor not greater than one, wherein the range of 0-1 is defined as a β-estradiol equivalent of less than 10 ng/g as defined by the Lumi-Cell™ test method.
10. A composition comprising a combination of: (a) at least one organic non- endocrine disrupting sunscreen agent; (b) an optional not endocrine disrupting emollient or mixtures thereof; and; (c) an optional inorganic, not-endocrine disrupting sun-block agent and; (d) an optional essential oil component comprising a carrier oil or an essential oil or both derived from an earth grown substance comprising no known endocrine disruptive agents; said composition capable of protecting skin from harmful effects of radiation including ultraviolet light or sunlight.
11. The composition according to claim 10, wherein said sunscreen agent is butyl- methoxydibenzoylmethane, said emollient is aloe barbadensis Miller or a single species of aloe or aloe barbadensis Miller-Stockton that includes high concentrations of oligosaccharides of aloe barbadensis Miller that inhibit loss of skin immunocompetency.
12. The composition according to claim 10, wherein active sunscreen agents, emollients, and carrier oils may include other not endocrine disruptive agents comprising a sunless tanning agent, an anti- microbial agent, a de-pigmentation agent, an anti-aging agent, an anti- fungal agent, and an insect repellent or any combination thereof, and; wherein one or more of the agents are topically active.
13. The composition according to claim 10, wherein said inorganic sun-block agents are sleeted from the group consisting of titanium dioxide, zinc oxide, silica or silicon dioxide or mixtures thereof and wherein said inorganic agents are micronized.
14. The composition according to claim 10, wherein said inorganic agents have a primary particle size of less than about 30 nanometers.
15. The composition according to claim 10, wherein said emollient is a salt of a fatty acid, where said salt of said fatty acid has been determined to be not endocrine disrupting.
16. The composition according to claim 10, wherein said composition has a pH range of 5 to about 8.5.
17. The composition according to claim 10, having a Sun Protection Factor (SPF) of at least 10, an immuno- responsiveness factor (IRF) of greater than zero, and a non-endocrine disrupter (NED) factor not greater than one, wherein the range of 0-1 is defined as a β- estradiol equivalent of less than 10 ng/g as defined by the Lumi-Cell™ test method.
18. A sunblock or sunscreen composition comprising cold pressed aloe vera gel, deionized water, micronized zinc oxide, vegetable derived glycerin, beeswax, ascorbic vitamin C palmitate, an enzyme concentrate, rose oil, tocopheryl vitamin E acetate, retinyl vitamin A palmitate, ergocalciferol (vitamin D), xanthan gum, magnesium silicate, grapefruit seed extract, rosemary extract, cinnamon extract, and bearberry extract.
19. A sunblock or sunscreen composition comprising; (a) a cyto-protective agent derived from an earth grown substance as determined by cytokine testing; and a composition containing at least one or more of the following additional substances; (b) sunflower oil, vegetable derived glycerin, coconut oil, stearic acid as extracted from vegetable fat, beeswax, orange wax, tocopheryl acetate, buttermilk powder, sodium borate, xanthan gum, honey, sucrose stearate, glucose, glucose oxidase, lactoperoxidase, and rosemary extract and an essential oil containing fragrance and wherein the composition includes blending and mixing with a zinc oxide or other suitable inorganic particles pre-dispersed in aloe barbadensis Miller and vegetable derived glycerine and SPF boosters to ensure SPF values greater than or equal to 15.
20. A UV-protective composition for topical administration, comprising: a) a sunscreen or sunblocking agent selected from zinc oxide, titanium dioxide, butyl-methoxydibenzoylmethane, and mixtures thereof, in an effective amount to provide a desired level of UV protection; b) glucose-rich mannose-containing oligosaccharides obtained from cold processed aloe barbadensis Miller, wherein the oligosaccharides are present in combination with glycerol, c) a component selected from the group consisting of sunflower oil, vegetable glycerin, coconut oil, stearic acid as extracted from vegetable fat, beeswax, orange wax, tocopheryl acetate, buttermilk powder, sodium borate, xanthan gum, sucrose stearate, glucose, glucose oxidase, lactoperoxidase, rosemary extract, and essential oil -containing fragrances; d) enzymes or enzyme mixtures that stabilize the composition by retarding or eliminating bacteria growth, and e) sufficient water to form an emulsion wherein, if zinc oxide or titanium oxide is present, it is in the form of a blended dispersion with aloe barbadensis Miller, and, optionally, vegetable derived glycerine and; wherein said composition further comprises SPF boosters to ensure SPF values greater than or equal to 15.
21. The composition of claim 20 wherein said composition is formulated into a solid, a liquid, an aerosol, a cream, a lotion, an ointment, a microemulsion, a solution, or a gel form.
22. The composition of claim 20, wherein said suncreen agent comprises not endocrine disrupting agents consisting of butyl-methoxydibenzoylmethane and/or other dibenzoyl ethers.
23. The composition of claim 19, wherein any or all the agents are immunoenhancing and/or cytoprotective.
24. A UV-protective composition for topical administration, comprising; at least one sun-block or sunscreen active agent in an amount effective to protect the skin against actinic radiation from sunlight;
(a) agents of the UV-protective compositions free of any known or suspected endocrine disrupters; (b) a non-endocrine disruptive, cytoprotective mixture made of earth grown substances, the mixture comprising glucose- rich mannose-containing oligosaccharide or oligosaccharides obtained from and used with aloe barbadensis Miller processed at or below room temperature within 45-90 minutes of harvesting, and; optionally components including; (c) one or more components selected from the group consisting of amino acids, vitamins or provitamins, nucleoderivatives, and vegetable extracts, wherein the amino acids comprise kyptophan, histidine, phenylalanine, tyrosine, the vitamins and provitamins comprising vitamin B6, vitamin A, vitamin E, tocopherols, betacarotene, bioflavonoids, nucleotides and polymers thereof, cascara, frangula, camomile, hyperic, calendula, elicriso, licorice or essential oils thereof, and;
(d) enough water to form a well mixed emulsion and;
(e) wherein the composition includes blending and mixing with a zinc oxide or other suitable inorganic particles dispersed in aloe barbadensis Miller and glycerine and optionally SPF boosters to ensure SPF values greater than 15.
25. A UV-protective composition for topical administration, comprising;
(a) at least one sunscreen or sun-block active agent to provide a desired amount of UV protection;
(b) agents of the UV protective compositions free of any known or suspected endocrine disrupters; (c) a not endocrine disrupting, cytoprotective mixture , the mixture comprising a glucose- rich mannose-containing oligosaccharide or oligosaccharides obtained from and used with aloe barbadensis Miller that can function as the at least one emollient, and;
(d) enough water to form a well mixed emulsion and
(e) wherein the composition includes blending and mixing with a zinc oxide or other suitable inorganic particles dispersed in aloe barbadensis Miller and glycerine and optionally SPF boosters to ensure SPF values greater than or equal to 15.
26. A UV-protective composition for topical administration, comprising; (a) adding optionally de-ionized water, undiluted cold pressed aloe barbadensis of a single species, and zinc oxide or titanium dioxide or silicon dioxide or silica or each individually or all in any combination to a vessel;
(b) then, adding a carrier oil; (c) then, mixing the resultant composition in said vessel.
27. The method of claim 26, comprising the steps of;
(a) adding de- ionized water, cold pressed aloe, and zinc oxide or titanium dioxide or silicon dioxide or silica or each individually or all in any combination to a vessel;
(b) then, adding a carrier oil and an emollient to said vessel; (c) then, mixing the resultant composition;
(d) maintaining (a)-(c) at or below 80 F then, maintaining or adjusting the pH of the composition to above 5.
28. The method of claim 26, comprising the steps of;
(a) adding cold pressed aloe, and zinc oxide or titanium dioxide or both in combination to a vessel;
(b) then, adding a carrier oil and an emollient and a thickener to said vesel;
(c) then, mixing the resultant composition; maintaining (a)-(c) at or below 80 F then, maintaining or adjusting the pH of the composition to above 5
29. A composition comprising sunscreen compositions containing sunscreen agents that provide non-endocrine disruptive, adequate, safe protection for mammalian skin while also enhancing the skin's immuno-responsiveness from cancerous or pre-cancerous skin cells in the presence of radiation such as UV light or sunlight.
30. A dispersion composition comprising an "all-natural" and primarily or all earth grown ingredient based dispersion of inorganic sunblocking agents that will ensure an SPF value of at least 15 or greater and wherein the dispersion must not have any endocrine disrupting agents or known toxins within said dispersion and wherein said dispersion is used to complete a sunblocking or sunscreen composition.
31. A test method for determining whether there are any endocrine disrupting ingredients, active or inactive, in a sunscreen or sun-block composition or any other composition used for sun protection, skin care, hair care, wherein said test method is the LUMI-CELL™ method.
32. A test method for using Applied-Kinesiology, comprising determining a response that any skin care composition has on a user's neuro-muscular strength, wherein the neuro- muscular testing diagnosis using Applied-Kinesiology is determining a composition's effect upon neuro-muscular response of a human exposed to said composition or any combination of compositions together with a LUMI-CELL™ test method, to ensure that all ingredients of said composition, including inactive and active ingredients used in said skin care composition are non-endocrine disrupting, non-toxic, and/or immunoenhancing, wherein a non-endocrine disrupter (NED) factor is determined to be not greater than one, wherein the range of 0-1 is defined as a β-estradiol equivalent of less than 10 ng/g as defined by said Lumi-Cell™ test method.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/005672 WO2008108756A1 (en) | 2007-03-05 | 2007-03-05 | Sunscreen compositions |
US12/449,932 US20100028276A1 (en) | 2007-03-05 | 2007-05-05 | Sunscreen compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/005672 WO2008108756A1 (en) | 2007-03-05 | 2007-03-05 | Sunscreen compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008108756A1 true WO2008108756A1 (en) | 2008-09-12 |
Family
ID=39738523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/005672 WO2008108756A1 (en) | 2007-03-05 | 2007-03-05 | Sunscreen compositions |
Country Status (2)
Country | Link |
---|---|
US (1) | US20100028276A1 (en) |
WO (1) | WO2008108756A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8795640B2 (en) | 2011-12-22 | 2014-08-05 | Mary Kay Inc. | Lip formulation |
WO2014203913A1 (en) * | 2013-06-18 | 2014-12-24 | L'oreal | Cosmetic composition |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120237466A1 (en) * | 2011-03-18 | 2012-09-20 | James Graham | Photo-filtering composition for hair and scalp |
DE102011006315A1 (en) * | 2011-03-29 | 2012-10-04 | Henkel Ag & Co. Kgaa | Detergents or cleaning agents with modified fragrances |
US20130149265A1 (en) * | 2011-12-09 | 2013-06-13 | Jennifer Lawandus | Sunscreen |
US9056063B2 (en) * | 2012-03-13 | 2015-06-16 | James E. Hanson | Natural sunscreen composition |
CN114276699B (en) * | 2022-01-10 | 2022-08-12 | 广州柏为科技有限公司 | Surface modification method of nano ZnO and application of nano ZnO in sunscreen cosmetics |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587150A (en) * | 1990-02-14 | 1996-12-24 | L'oreal | Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate |
WO1996041614A1 (en) * | 1995-06-08 | 1996-12-27 | Johnson & Johnson Consumer Products, Inc. | Sunscreen compositions |
US20040247543A1 (en) * | 2001-09-21 | 2004-12-09 | Playtex Products, Inc. | Sunscreen compositions |
US20060233725A1 (en) * | 2001-08-09 | 2006-10-19 | Grune Guerry L | Non-Endocrine Disrupting Cytoprotective UV Radiation Resistant Substance |
-
2007
- 2007-03-05 WO PCT/US2007/005672 patent/WO2008108756A1/en active Application Filing
- 2007-05-05 US US12/449,932 patent/US20100028276A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587150A (en) * | 1990-02-14 | 1996-12-24 | L'oreal | Photostable cosmetic screening composition containing a UV-A screening agent and an alkyl β, β-diphenylacrylate or α-cyano-β,β-diphenylacrylate |
WO1996041614A1 (en) * | 1995-06-08 | 1996-12-27 | Johnson & Johnson Consumer Products, Inc. | Sunscreen compositions |
US20060233725A1 (en) * | 2001-08-09 | 2006-10-19 | Grune Guerry L | Non-Endocrine Disrupting Cytoprotective UV Radiation Resistant Substance |
US20040247543A1 (en) * | 2001-09-21 | 2004-12-09 | Playtex Products, Inc. | Sunscreen compositions |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8795640B2 (en) | 2011-12-22 | 2014-08-05 | Mary Kay Inc. | Lip formulation |
WO2014203913A1 (en) * | 2013-06-18 | 2014-12-24 | L'oreal | Cosmetic composition |
Also Published As
Publication number | Publication date |
---|---|
US20100028276A1 (en) | 2010-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1341147C (en) | Sunscreen compositions | |
US9095522B2 (en) | High SPF transparent or translucent, cytoprotective, biodegradable, UV radiation resistant compositions | |
US20100028276A1 (en) | Sunscreen compositions | |
US20050196361A1 (en) | Non endocrine disrupting cytoprotective UV radiation resistant composition | |
US20150110724A1 (en) | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions | |
US5910311A (en) | Composition containing a non-photocatalytic metal oxide and tocopherol, its use in the cosmetics and/or dermatological field and processes employing it | |
US6048517A (en) | High SPF sunscreen formulations | |
US20080219938A1 (en) | SPF compositions | |
CZ396997A3 (en) | Composition providing protective sun filter | |
AU5194700A (en) | Additive for improving the water resistance of cosmetic or dermatological formulations | |
FR2577805A1 (en) | SKIN TREATMENT COMPOSITION BASED ON HYDROQUINONE GLUCOSIDE | |
US9782610B2 (en) | Nontoxic, non-endocrine disrupting, cytoprotective, UV-radiation resistant sunblock compositions | |
JPH0899820A (en) | Skin external agent | |
WO2008136889A1 (en) | High spf transparent or translucent, cytoprotective, biodegradable, uv radiation resistant compositions | |
US20100055054A1 (en) | Self tanning compositions containing oils | |
KR101917774B1 (en) | A preservative composition of cosmetics comprising Nigella sativa seed extract as an active ingredient | |
CN108014060B (en) | Sunscreen synergistic composition and application thereof | |
JPH07101844A (en) | Multilayered emulsion | |
KR20150106244A (en) | UV protection and moisturizing cosmetic composition | |
JP3452671B2 (en) | External preparation for skin | |
CN108186478B (en) | Composition capable of improving sun-screening effect and application thereof | |
CN114522119A (en) | Composition containing water-dispersible sunscreen agent and application thereof | |
CN112120988A (en) | Whitening sunscreen lotion and preparation method thereof | |
US20150366777A1 (en) | Combination of skin protection against damages caused by infrared radiation | |
Barluado | Formulation and Sun Protection Factor Estimation of Squash Cucurbita maxima Seeds Sunblock Lotion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07873401 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12449932 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07873401 Country of ref document: EP Kind code of ref document: A1 |